These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 8303754)
1. Safety study of tirilazad mesylate in patients with acute ischemic stroke (STIPAS). STIPAS Investigators Stroke; 1994 Feb; 25(2):418-23. PubMed ID: 8303754 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of tirilazad in aneurysmal subarachnoid hemorrhage. A report of the Cooperative Aneurysm Study. Haley EC; Kassell NF; Alves WM; Weir BK; Hansen CA J Neurosurg; 1995 May; 82(5):786-90. PubMed ID: 7714603 [TBL] [Abstract][Full Text] [Related]
3. A randomized trial of tirilazad mesylate in patients with acute stroke (RANTTAS). The RANTTAS Investigators. Stroke; 1996 Sep; 27(9):1453-8. PubMed ID: 8784112 [TBL] [Abstract][Full Text] [Related]
4. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part I. A cooperative study in Europe, Australia, New Zealand, and South Africa. Lanzino G; Kassell NF; Dorsch NW; Pasqualin A; Brandt L; Schmiedek P; Truskowski LL; Alves WM J Neurosurg; 1999 Jun; 90(6):1011-7. PubMed ID: 10350245 [TBL] [Abstract][Full Text] [Related]
5. Randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in Europe, Australia, and New Zealand. Kassell NF; Haley EC; Apperson-Hansen C; Alves WM J Neurosurg; 1996 Feb; 84(2):221-8. PubMed ID: 8592224 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, vehicle-controlled trial of tirilazad mesylate in patients with aneurysmal subarachnoid hemorrhage: a cooperative study in North America. Haley EC; Kassell NF; Apperson-Hansen C; Maile MH; Alves WM J Neurosurg; 1997 Mar; 86(3):467-74. PubMed ID: 9046304 [TBL] [Abstract][Full Text] [Related]
7. Double-blind, randomized, vehicle-controlled study of high-dose tirilazad mesylate in women with aneurysmal subarachnoid hemorrhage. Part II. A cooperative study in North America. Lanzino G; Kassell NF J Neurosurg; 1999 Jun; 90(6):1018-24. PubMed ID: 10350246 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: II. Multiple-dose administration. Fleishaker JC; Peters GR; Cathcart KS; Steenwyk RC J Clin Pharmacol; 1993 Feb; 33(2):182-90. PubMed ID: 8440768 [TBL] [Abstract][Full Text] [Related]
9. Multiple-dose tolerability and pharmacokinetics of tirilazad mesylate at doses of up to 10 mg/kg/day administered over 5-10 days in healthy volunteers. Fleishaker JC; Hulst LK; Peters GR Int J Clin Pharmacol Ther; 1994 May; 32(5):223-30. PubMed ID: 7921515 [TBL] [Abstract][Full Text] [Related]
10. Amelioration of impaired cerebral metabolism after severe acidotic ischemia by tirilazad posttreatment in dogs. Kim H; Koehler RC; Hurn PD; Hall ED; Traystman RJ Stroke; 1996 Jan; 27(1):114-21. PubMed ID: 8553386 [TBL] [Abstract][Full Text] [Related]
11. Therapeutic efficacy of tirilazad in experimental multiple cerebral emboli: a randomized, controlled trial. Clark WM; Hotan T; Lauten JD; Coull BM Crit Care Med; 1994 Jul; 22(7):1161-6. PubMed ID: 8026207 [TBL] [Abstract][Full Text] [Related]
12. Tirilazad mesylate in acute ischemic stroke: A systematic review. Tirilazad International Steering Committee. Stroke; 2000 Sep; 31(9):2257-65. PubMed ID: 10978061 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of the pharmacokinetics and tolerability of tirilazad mesylate, a 21-aminosteroid free radical scavenger: I. Single-dose administration. Fleishaker JC; Peters GR; Cathcart KS J Clin Pharmacol; 1993 Feb; 33(2):175-81. PubMed ID: 8382708 [TBL] [Abstract][Full Text] [Related]
14. Tirilazad reduces cortical infarction after transient but not permanent focal cerebral ischemia in rats. Xue D; Slivka A; Buchan AM Stroke; 1992 Jun; 23(6):894-9. PubMed ID: 1595111 [TBL] [Abstract][Full Text] [Related]
15. The effect of tirilazad mesylate on infarct volume of patients with acute ischemic stroke. van der Worp HB; Kappelle LJ; Algra A; Bär PR; Orgogozo JM; Ringelstein EB; Bath PM; van Gijn J; ; Neurology; 2002 Jan; 58(1):133-5. PubMed ID: 11781420 [TBL] [Abstract][Full Text] [Related]
16. Lazaroids. CNS pharmacology and current research. Clark WM; Hazel JS; Coull BM Drugs; 1995 Dec; 50(6):971-83. PubMed ID: 8612475 [TBL] [Abstract][Full Text] [Related]
17. The effect of tirilazad mesylate (U74006F) on cerebral oxygen consumption, and reactivity of cerebral blood flow to carbon dioxide in healthy volunteers. Olsen KS; Videbaek C; Agerlin N; Krøll M; Bøge-Rasmussen T; Paulson OB; Gjerris F Anesthesiology; 1993 Oct; 79(4):666-71. PubMed ID: 8214745 [TBL] [Abstract][Full Text] [Related]
18. Effect of age and gender on tirilazad pharmacokinetics in humans. Hulst LK; Fleishaker JC; Peters GR; Harry JD; Wright DM; Ward P Clin Pharmacol Ther; 1994 Apr; 55(4):378-84. PubMed ID: 8162663 [TBL] [Abstract][Full Text] [Related]
19. Effects of the 21-amino steroid tirilazad mesylate (U-74006F) on brain damage and edema after perinatal hypoxia-ischemia in the rat. Bågenholm R; Andiné P; Hagberg H Pediatr Res; 1996 Sep; 40(3):399-403. PubMed ID: 8865275 [TBL] [Abstract][Full Text] [Related]
20. Administration of methylprednisolone for 24 or 48 hours or tirilazad mesylate for 48 hours in the treatment of acute spinal cord injury. Results of the Third National Acute Spinal Cord Injury Randomized Controlled Trial. National Acute Spinal Cord Injury Study. Bracken MB; Shepard MJ; Holford TR; Leo-Summers L; Aldrich EF; Fazl M; Fehlings M; Herr DL; Hitchon PW; Marshall LF; Nockels RP; Pascale V; Perot PL; Piepmeier J; Sonntag VK; Wagner F; Wilberger JE; Winn HR; Young W JAMA; 1997 May; 277(20):1597-604. PubMed ID: 9168289 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]